FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma  

On December 3,2021, the Food and Drug Administration  approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of adult and pediatric (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection.

Source: FDA Center for Drug Evaluation and Research - What's New - December 3, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news